Eröffnen Sie jetzt Ihr Depot und Bankkonto bei
cash – banking by bank zweiplus in 5 Schritten.Trading-Konto eröffnen
Eröffnen Sie jetzt Ihr Depot und Bankkonto bei
cash – banking by bank zweiplus in 5 Schritten.Trading-Konto eröffnen
Der Kommentar von Emil wurde ignoriert. Um die Kommentare von Emil wieder zu sehen, klicken Sie folgenden Link:
27. Juni 2018
Der Kommentar von Selector wurde ignoriert. Um die Kommentare von Selector wieder zu sehen, klicken Sie folgenden Link:
Ja, hier geht was zurzeit:
Aurora Cannabis to acquire 8% of Choom Holdings
2018-06-13 08:02 ET - News Release
Mr. Terry Booth reports
AURORA CANNABIS TO BE LEAD INVESTOR IN CHOOM HOLDINGS PRIVATE PLACEMENT
Aurora Cannabis Inc. intends to complete a $7-million investment in Choom Holdings Inc., whereby Aurora will receive 9,859,155 common shares from Choom's treasury, priced at 71 cents per share, representing an 8-per-cent ownership interest.
Choom currently operates two late-stage applicants under the Access to Cannabis for Medical Purposes Regulations (ACMPR). Choom has agreements in place to acquire two additional late-stage applicant craft growers in British Columbia and Saskatchewan, including a facility in Sooke, B.C., anticipated to receive its cultivation licence from Health Canada in the third quarter of 2018.
The relationship between Aurora and Choom germinated through Aurora Pro, the platform through which the company delivers a variety of services to industry participants, including cultivation, genetics, regulatory consultancy and market development services. The Aurora Pro platform was developed by Aurora to interact with craft growers who are faced with potentially unreasonable entry barriers to the adult usage market in Canada.
Choom's strategy is to develop a carefully curated portfolio of high-grade cannabis strains with ideal characteristics for craft growing, targeting the premium segment of the adult consumer use market. Choom continues to develop a sophisticated brand, high-grade products and an elevated in-store customer experience. Images of the company's concept cannabis retail outlets can be found on-line.
To date, Choom has secured rights to 17 retail leases in highly defensible locations throughout Alberta. Applications to obtain a cannabis retail licence for these outlets have been submitted. Choom also has seven leases secured in B.C. and licences will be applied for upon commencement of the licensing program in B.C. Choom furthermore intends to play an important role in the Saskatchewan retail market and has a robust strategy in place to develop its presence in this market.
"Our investment in a consumer-focused brand with a strong retail strategy offers Aurora additional growth opportunities through supply, retail and distribution to the adult consumer use market, and provides a good example of the functioning of Aurora Pro," said Terry Booth, chief executive officer of Aurora. "Choom has established a well-developed brand, supported by deep roots within the British Columbia cannabis community and a passion for high-grade, handcrafted product. We're excited to strengthen our relationship with the team at Choom and help amplify their market reach as they continue to execute on their differentiated craft growing philosophy and their unique retail strategy."
Chris Bogart, president and CEO for Choom, added: "Teaming up with what we consider to be the most dynamic licensed producer with exceptional strength throughout the entire cannabis value chain, we believe, will prove to be a key growth accelerator for Choom. Both companies have a very strong focus on the entire customer experience, key in establishing exceptional brands. This investment by Aurora is a strong signal to our markets and our shareholders that Choom's strategy meets with the highest standards in the industry."
About Aurora Cannabis Inc.
Aurora's wholly owned subsidiary, Aurora Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada's Access to Cannabis for Medical Purposes Regulations (ACMPR). The company operates a 55,200-square-foot, state-of-the-art production facility in Mountain View county, Alberta, known as Aurora Mountain, and a second 40,000-square-foot high-technology production facility known as Aurora Vie in Pointe-Claire, Que., on Montreal's West Island. In January, 2018, Aurora's 800,000-square-foot flagship cultivation facility, Aurora Sky, located at the Edmonton International Airport, was licensed by Health Canada. Once at full capacity, Aurora Sky is expected to produce over 100,000 kilograms per annum of cannabis.
About Choom Holdings Inc.
Choom was created for and inspired by the Choom gang, a group of buddies in Honolulu during the 1970s who loved to smoke weed -- or as the locals called it, choom. Now, after four decades, Choom is bringing the spirit of Hawaii to Canada. Choom is focused on delivering an elevated customer experience through its curated retail environments, high-grade handcrafted cannabis supply and a diversity of brands for the Canadian recreational consumer.
We seek Safe Harbor.
© 2018 Canjex Publishing Ltd. All rights reserved.
Dann war da noch:
Der Kommentar von Lorenz wurde ignoriert. Um die Kommentare von Lorenz wieder zu sehen, klicken Sie folgenden Link:
Hier kommt heute scon wieder Erfreuliches:
Aurora Cannabis to Acquire Cannabis Science Leader Anandia Laboratories Inc.
Aurora Cannabis Inc. (“Aurora” or the “Company”) (ACB.TO) (ACBFF) ( Frankfurt : 21P; WKN: A1C4WM) and Anandia Laboratories Inc. (“Anandia“) announced today that they have signed a binding term sheet whereby Aurora intends to acquire all of the issued and outstanding common shares of privately-held Anandia in an all share transaction valued at approximately $115 million on a fully diluted basis (the “Transaction”).
Led by CEO and co-founder Jonathan Page , PhD, one of the industry’s most widely recognized cannabis experts, Anandia is considered the industry leader in science, genetics, and independent cannabis product testing. Dr. Page was the first scientist to sequence the cannabis genome and provide deep insights into the biosynthesis of cannabinoids and the interplay between cannabinoids and terpenes.
Anandia’s COO and co-founder, John Coleman , PhD, brings over 20 years of experience in drug research and commercialization as a natural product chemist. He previously worked in the biotech industry, most recently leading the team identifying new drug targets for the federally funded Centre for Drug Research and Development.
Anandia’s intellectual property (“IP”) includes the exclusive rights to a number of key genes in the cannabinoid pathway, as well as patents pending for genetic markers. The strength of Anandia’s expert staff, proprietary assets and know-how will provide Aurora with a very significant advantage in developing new cannabis cultivars. For instance, genome-based variety development and technological fortification can tailor metabolite (cannabinoid and terpene) profiles, improve disease resistance, enhance crop yield and optimize flowering time, and can be employed to develop specialized cultivars for oil production.
In advance of the forthcoming legalization of the adult use market and the significant associated growth, Anandia intends to expand its R&D, product testing, and product development facilities to meet both domestic and international demand, including the development of:
Anandia follows a three-pronged approach to creating value for its clients licensed under Canada’s Access to Cannabis for Medical Purposes Regulations (“ACMPR”) and intends to continue to do so following completion of the Transaction:
Combining with Aurora gives Anandia access to significant new market opportunities in Canada and internationally through Aurora’s global footprint. Furthermore, leveraging Aurora’s capabilities and capacity in facility development, the combination will accelerate the construction of Anandia’s testing and product development laboratory in Vancouver , and a unique, purpose-built cannabis breeding facility ahead of Canadian adult-use legalization,
Anandia’s Product Testing
Anandia’s cannabis testing services will remain operationally independent of Aurora. These services will remain intact and Anandia is committed to continuing to serve all clients, including Licensed Producers and patient-growers, and Anandia is committed to maintaining complete data confidentiality. Anandia will continue to build capacity to take on the increased sample volume arising from legalization, including expansion to its new testing facility in Vancouver .
“This is a transformative acquisition that expands our science capabilities in the upstream segment of the seed-to-sale cannabis value chain, significantly boosting plant-based innovations in cultivation, enabling accelerated product development, and, ultimately, enhancing our margin profile going forward,” said Terry Booth , CEO of Aurora. “Anandia has a fantastic, complementary corporate culture and some of the best and brightest minds in the cannabis industry, including Dr. Jonathan Page , the first scientist to sequence the cannabis genome. By adding Dr. Page and the Anandia team to the existing Aurora and CanniMed research infrastructure, we are assembling a unique, world-class research group to capitalize on the many exciting opportunities the cannabis plant offers society.”
Dr. Jonathan Page , Anandia’s co-founder and CEO, added, “Anandia is already on its way to developing a world-leading library of cannabis genetics coupled with in-depth genomic analysis. We expect our breeding efforts to be accelerated through access to Aurora’s financial resources and scientific expertise, as well as through the addition of Aurora’s multiple cultivation sites. Anandia and Aurora are strong believers in research and science-based solutions. Joining forces with Aurora allows us to continue to provide best-in-class testing services to our customers, while rapidly advancing cannabis science for the benefit of patients, consumers and growers.”
Und von gestern noch dies:
Hier noch was von CGC (ich habe momentan grad keine, warte mal, wie das so kommt an der US-Börse)
Canopy to go ahead with pot trials to treat insomnia
2018-06-12 09:58 ET - News Release
Mr. Mark Zekulin reports
MEDICAL CANNABIS LEADERSHIP FROM CANOPY GROWTH AND SUBSIDIARY SPECTRUM CANNABIS
Canopy Growth Corp. has provided the following updates on its medical cannabis program and has reaffirmed its strong commitment to medical cannabis, the patients who depend on it and the health care professionals who prescribe it.
Historic clinical trial milestones
Marking a major milestone for medical cannabis in Canada, a phase IIb in-human clinical trial application was submitted by Canopy Health Innovations Inc. to evaluate the use of medical cannabis in the treatment of insomnia. Having received approval to proceed with these clinical trials in the form of a no objection letter (NOL) from Health Canada, Canopy Health will now proceed with these robust clinical trials, in collaboration with a leading Canadian research institution.
In light of the significant potential for cannabis in treating a range of medical conditions, this is the first in a planned series of trials to investigate and quantify the therapeutic effect of cannabis and cannabinoids across a selection of indications with significant unmet needs, working toward the ultimate goal of patented, insurance-eligible cannabinoid-based medicines.
World-class leadership for a global industry
As previously announced, starting in July, 2018, Dr. Mark Ware will commence his role as the company's chief medical officer. Under his leadership the company will continue to lead the global medical cannabis industry forward with a focus on research, product innovation and stakeholder education in the numerous regions where Spectrum Cannabis operates, including Latin America, Australia, Europe and North America.
Patients-first pricing mentality
Honouring the company's commitment to affordable medical cannabis and pricing predictability for patients, Canopy Growth is pleased to inform patients that, upon the passing of the Cannabis Act, the company will absorb the proposed excise tax on all Spectrum Cannabis products sold in Canada. Affordability is a key consideration for patients. It is important today to show leadership and reduce the price burden placed on customers, while the company works toward insurance eligibility for medical cannabis.
On top of this, all Spectrum Cannabis dried flower products will be priced at $8.50 per gram or less. If a registered customer is currently paying more for a Spectrum flower product this means new savings, and if they are paying less that price will remain the same. As always, Spectrum Cannabis products available on-line through the Tweed Main Street website are eligible for the company's industry-first compassionate pricing program that assists those on limited incomes afford their medicine.
"Using Canada's rich ecosystem of researchers and established cannabis stakeholders as a centre of expertise, Spectrum's global expansion is rooted in sophistication," said Mark Zekulin, president, Canopy Growth. "We are proudly a research- and patient-focused company that will continue to drive the cannabis innovation agenda forward around the world."
Here is to future growth.
About Canopy Growth Corp.
Canopy Growth is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and softgel capsule forms. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time.
Und von gestern die News.
Der Kommentar von petra129 wurde ignoriert. Um die Kommentare von petra129 wieder zu sehen, klicken Sie folgenden Link:
Eigentlich nicht....es war nur etwas Unruhe in den kanadischen Foren wegen diesen Wahlen - und bei mir auch. Aber heute hat Herr T. etwas von sich gegeben, was eher beruhigt, allerdings bei ihm weiss man nie....
Trump says he is likely to support ending federal ban on marijuana
...und das ist natürlich erfreulich - thanx
Aurora Cannabis Inc. has commented on June 7, 2018, Canadian Senate vote in favour of Bill C-45, which governs the legalization of the adult consumer use of cannabis.
Wolltest bestimmt was einfügen ?
Ich habe hier noch eine Info von heute:
Aurora Cannabis pleased with passage of Bill C-45
2018-06-08 04:40 ET - News Release
AURORA CANNABIS WELCOMES HISTORIC SENATE VOTE TO LEGALIZE THE ADULT USAGE OF CANNABIS IN CANADA
"This truly is a monumental day for Canada and the cannabis movement, with the ground-breaking Senate vote to pass Bill C-45 representing a major milestone, strengthening our global leadership in the cannabis sector, and making this country the first in the Group of Seven Nations (G7) to take this historic step," said Terry Booth, CEO. "We applaud the government's intelligent and rational public policy, initiating wholesale legislative changes - focused on clearly defined objectives - to reduce the negative impact of prohibition, while establishing a well-regulated system designed to protect public health and public safety. We must also salute and congratulate the advocates, the activists and the passionate who for decades, and often at great personal risk, spoke up, sat in, appealed laws, wrote new ones, ran studies, educated, and changed perceptions towards ending criminal prohibition."
"We are very pleased with today's vote, but more important work remains, particularly with respect to how our industry is allowed to operate and profile itself in order to meet Canadian adult consumer expectations," added Mr. Booth. "In addition, with legalization alone, the burden of prior non-violent cannabis-related convictions and charges will continue to carry a significant and unacceptable negative impact on many Canadians, disproportionately affecting individuals from marginalized populations. Aurora believes the government must now urgently consider amnesty for non-violent cannabis-related offenses, and will continue advocating on this important topic. Furthermore, we will continue our advocacy to obtain tax-exempt status for medical cannabis in support of Canada's patients whose quality of life has greatly improved through cannabis-based therapies. Medical cannabis currently is the sole prescribed medicine in Canada upon which any tax is charged, and we will continue our pursuit to correct this oversight."
Mr. Booth concluded, "With the implementation of Bill C-45 around the corner, we will continue our high-paced execution and deliver innovations, industry-leading customer care, and rapidly growing production capacity to this significant and exciting market. We will bring the Aurora Standard to the adult consumer market, delivering a uniquely satisfying customer experience."
Aurora Cannabis Enters into Global Softgel Business with Capcium Inc.
Strategic Investment Secures 19.99% Ownership of a Softgel Production Leader
EDMONTON, June 7, 2018 - Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) and Capcium Inc. ("Capcium") announced today that the companies have signed a strategic agreement to produce high quality cannabis-based softgels for patients. Additionally, Aurora has acquired a 19.99% ownership interest in Capcium by way of a non-brokered private placement for consideration of $10 million.
Capcium, a privately-owned Montreal-based global leader in softgel manufacturing, has emerged as one of the leading manufacturers in the cannabis industry. Production of high-precision dosage controlled softgels is an extensive and complex process. Capcium, through its pharmaceutical and encapsulation experience, has developed expertise that is ready to be applied to the cannabis industry and deliver high-volume production capacity.
Capcium intends to use the proceeds from the Aurora investment to expand its cutting-edge cannabis softgel manufacturing business, which includes the construction and operation of a large, state-of-the-art facility, to be completed in Q4, 2019.
In advance of this new Capcium facility, and to accelerate time to market, Capcium and Aurora have agreed to immediately establish a high-volume, state-of-the-art softgel manufacturing operation at Aurora Vie, the Company's cannabis production facility in Pointe-Claire, Québec. Softgel sales from this facility are anticipated to commence (subject to Health Canada approval) by the end of Summer 2018. Capcium will be the exclusive manufacturer of Aurora's North American cannabis softgel products. The agreement also contemplates Capcium being the company's preferred global manufacturer of softgel cannabis products.
"This investment in Capcium reflects our strategic objective to further expand our differentiated, higher-margin product offerings," said Terry Booth, CEO of Aurora. "Capcium's extensive know-how has enabled it to develop an advanced technology for the high-volume production of cannabis-based softgels. This provides us with a strong competitive advantage, positioning us well to build a leading position in the production and sale of value-added cannabis products globally. We are proud that Aurora quickly is becoming the partner of choice in the cannabis industry, and we look forward to capitalizing with Capcium on the significant opportunity that softgels represent."
Sylvain Duvernay, CEO of Capcium, added, "Teaming up with what we believe to be the most innovative Licensed Producer with excellent international distribution channels, greatly enhances our growth prospects. We are delighted that Aurora and Capcium will become long-term partners, and look forward to bringing Québec made softgel cannabis products to Canada and to the global markets."
Aurora and Capcium believe the benefits of the transaction are significant for all shareholders. Aurora's brand leadership, quality products, customer care, innovation and deep product knowledge will be a strong complement to Capcium's well-established softgel manufacturing expertise. This deal will establish Québec as a world leader for cannabis value added products by leveraging the experience and expertise of two innovative companies with Québec operations, while creating highly-skilled Québec-based employment in the rapidly expanding cannabis sector.
Terms of the Investment
Aurora has made an initial $10 million investment in Capcium by way of a non-brokered private placement. The consideration paid by Aurora consists of $500,000 in cash and $9.5 in million common shares of Aurora at a five-day volume weighted average trading price of Aurora's Common Shares on the Toronto Stock Exchange (the "TSX") for the period ended June 6, 2018. Upon completion of the investment, Aurora will own approximately 19.99% of the issued and outstanding common shares of Capcium.
The private placement is subject to the final approval of the TSX, and is not subject to any financing or due diligence conditions.
Aurora's wholly-owned subsidiary, Aurora Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada's Access to Cannabis for Medical Purposes Regulations ("ACMPR"). The Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta, known as "Aurora Mountain", and a second 40,000 square foot high-technology production facility known as "Aurora Vie" in Pointe-Claire, Quebec on Montreal's West Island. In January 2018, Aurora's 800,000 square foot flagship cultivation facility, Aurora Sky, located at the EdmontonInternational Airport, was licensed. Once at full capacity, Aurora Sky is expected to produce over 100,000 kg per annum of cannabis. Aurora is completing a facility in Lachute, Quebec utilizing its wholly owned subsidiary Aurora Larssen Projects Inc.
The Company's wholly-owned subsidiary CanniMed Therapeutics Inc. ("CanniMed") is Canada's most experienced licensed producer of medical cannabis, with over 20,000 kg per annum in funded capacity. CanniMed forms the heart of Aurora's Medical Cannabis Centre of Excellence, aimed at product and market development.
Aurora owns Berlin-based Pedanios GmbH, the leading wholesale importer, exporter, and distributor of medical cannabis in the European Union. The Company owns 51% of Aurora Nordic, which will be constructing a 1,000,000 square foot hybrid greenhouse in Odense, Denmark. The Company offers further differentiation through its acquisition of BC Northern Lights Ltd. and Urban Cultivator Inc., industry leaders, respectively, in the production and sale of proprietary systems for the safe, efficient and high-yield indoor cultivation of cannabis, and state-of-the-art indoor gardening appliances for the cultivation of organic microgreens.
Aurora holds a 25% ownership interest in Alcanna Inc. ("CLIQ"), one of Western Canada's largest retail chains of liquor stores. The Company holds approximately 17.02% of the issued shares in leading extraction technology company Radient Technologies Inc, and holds 52.7% of Hempco Food and Fiber Inc. Aurora is also the cornerstone investor in two other licensed producers, with a 22.9% stake in Cann Group Limited, the first Australian company licensed to conduct research on and cultivate medical cannabis, and a 17.62% stake in Canadian producer The Green Organic Dutchman Ltd., with options to increase to majority ownership. Finally, the Company owns a 9.14% stake in CTT Pharmaceutical, an innovative product development company within the cannabis space.
Aurora's Common Shares trade on the TSX under the symbol "ACB", and are a constituent of the S&P/TSX Composite Index
Capcium Inc. is a Montreal based contract manufacturing platform specializing in softgel encapsulation. Capcium is transforming the cannabis industry by providing high-value, high quality cannabis products. Capcium presently holds a nutraceutical license from Health Canada and will soon apply to be fully licensed for cannabis in its new state-of-the-art manufacturing facility in Pointe Claire, Quebec.
Niederlage für Trudeau - Konservativer wird Premierminister von Ontario
Ontario ist die bevölkerungsreichste Provinz Kanadas. Wer dort regiert, hat starken Einfluss auf die Politik des Landes.
Autor: Daniel Voll
Heute, 08:04 Uhr
.....hoffentlich wirkt sich das nicht zu sehr auf die Hemp-Aktien aus.....
Dies wollte ich noch mitteilen:
Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual event through VirtualInvestorConferences.com
EDMONTON, Alberta, June 5, 2018 /CNW/ -- Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) today announced that Cam Battley, Chief Corporate Officer will present live at VirtualInvestorConferences.com on June 7, 2018.
DATE: Thursday, June 7, 2018TIME: 12:00 PM ETLINK: https://tinyurl.com/0618prepr
This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as well as the association's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.
It is recommended that investors pre-register and run the online system check to save time and receive event updates.
Recent Company Highlights
The Cannabis Virtual Investor Conference on June 7, 2018 is made possible by a partnership between KCSA Strategic Communications and VirtualInvestorConferences.com. Learn more about the event at www.VirtualInvestorConferences.com.
Du hast Recht, man sollte Aurora auch nicht aus den Augen lassen, ich habe sie. (Bei CGC/WEED) bin ich seit dem US-Börsenstart mal weg).
Aurora Cannabis Launches New Cannabis Product Line – Aurora Frost
Aurora Cannabis Inc. (“Aurora” or the “Company”) (ACB.TO) (ACBFF) ( Frankfurt : 21P; WKN: A1C4WM) today announces the launch of new product line called Aurora Frost . This new dried cannabis product line represents the highest potency offering of any Aurora product launched to date at over 35% THC.
Aurora Frost products are produced from premium whole flower. The products, generally known throughout the industry as kief, consist primarily of trichomes, the resinous glands rich in active pharmaceutical ingredients, including terpenes, flavonoids, and cannabinoids, such as THC and CBD.
Aurora’s in-house technology team successfully developed a new and proprietary technology used to efficiently produce high volume, GMP compliant, Aurora Frost products, based on a process that finely trims the trichomes from the cannabis flower.
Beginning today, Aurora Frost is shipping in convenient, child-safe, certified glass bottles. Products are sold in one gram increments, priced at $35 per gram ( $25 per gram for compassionate pricing patients). Like all Aurora products, Aurora Frost comes with publicly available third party independent laboratory results on potency, terpene profile, and contaminant analysis.
“Successfully developing a proprietary, fine trimming and GMP compliant technology needed to produce these high-quality products at commercial scale, provides us with a remarkable advantage in addressing this niche of the cannabis market,” said Terry Booth , CEO. “Aurora now makes this high potency medical cannabis available to its patients, reflecting the Aurora Standard of innovation and patient care.”
SMITHS FALLS, ON, May 30, 2018 /CNW/ - Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) ("Canopy Growth" or the "Company") is pleased to announce that the Company has acquired Daddy Cann Lesotho PTY Ltd., trading as Highlands ("Highlands").
Based in the Kingdom of Lesotho ("Lesotho"), Highlands holds a license to cultivate, manufacture, supply, hold, import, export and transport cannabis and its resin. Lesotho is a high altitude mountainous kingdom that boasts over 300 days of sunshine per year and was the first African nation to legalize medical cannabis in 2017. It has ideal humidity and growing conditions for greenhouse cultivation. Together with very low operating and resource costs, this places Canopy Growth in a position to produce large quantities of high quality medical cannabis at a low cost. Lesotho is also strategically positioned for the future medical cannabis economy of Southern Africa including the potential market of South Africa, with a population of over 55 million people, where medical cannabis laws are being developed.
"Lesotho is Canopy Growth's first step into Africa and we look forward to working with the strong local team at Highlands to establish production and distribution capabilities consistent with Canopy's global standard for high-quality, regulated medical cannabis products," said Mark Zekulin, President, Canopy Growth.
Combining the domestic and regional knowledge of Highlands with the global experience and expertise of Canopy Growth is the latest example of the Company establishing a meaningful local presence. With the objective of future local production to serve the regional market, these operations are part of Canopy Growth's commitment to the Lesotho economy including supporting job creation and lasting community engagement.
All key members of Highlands's management team will continue to lead the organization as part of the Canopy Growth family.
"We're excited to join the Canopy Growth family and bring together our strong entrepreneurial experience and local knowledge in the region with Canopy Growth's track record and quality standards in the global medical cannabis industry," said Jody Aufrichtig, Founder, Highlands. "Lesotho and Southern Africa have enormous potential and we look forward to building a responsible medical cannabis business across the region."
Under the terms of the agreement, the Company issued 666,362 common shares in the capital of the Company to the sole shareholder of Highlands on closing and, subject to meeting certain milestones, the Company will issue up to an additional 333,281 common shares to the sole shareholder of Highlands for a total of up to 999,643 common shares based on the 30 day volume weighted average price of $28.763 of Canopy Growth's common shares on the TSX as of May 11, 2018. The total value of the consideration payable by the Company under the terms of the agreement is approximately $28.8 million.
This marks the fifth continent of operations for Canopy Growth who has market presence in North and South America, Oceania, Europe, and now Africa.
Here's to Future Growth (in Southern Africa).
Heute gesehen, zum Aussuchen - oder beides:
Aurora Cannabis signs distribution deal in Germany
2018-05-28 07:55 ET - News Release
AURORA CANNABIS SIGNS AGREEMENT WITH HEINRICH KLENK GMBH & CO. KG
Aurora Cannabis Inc., through its wholly owned subsidiary Pedanios GmbH, has signed a collaboration agreement with Heinrich Klenk GmbH & Co. KG, one of Europe's largest medicinal plant companies. Klenk, whose products are carried in over 25,000 pharmacies throughout Germany and Europe, has been importing, exporting and processing medicinal plants and herbal raw materials for the pharmaceutical industry for over 90 years.
Under the terms of the agreement, Aurora has launched a new cannabis brand in Germany called Cannabis Klenk which is produced in Canada, imported by Pedanios, and sold to German pharmacies through Klenk's existing and wide-reaching pharmaceutical wholesale distribution network. Klenk has an unmatched reputation in Germany, both for the quality of its products, and for the reliability of its distribution network.
"Klenk is a fantastic partner for Aurora, enabling us to add to our already leading presence in the German market with one of the country's most widely recognized medicinal plant brands and most comprehensive distribution networks," said Neil Belot, chief global business development officer. "Operating for over 90 years, Klenk is one of the most trusted partners to the pharmaceutical wholesale and pharmacy sectors. This, we believe, will help further destigmatize the use of medical cannabis in Germany and accelerate growth. Klenk's decentralized distribution capabilities ensure short supply lines throughout the entire country, greatly increasing our market reach, while reducing the need to invest heavily in our own sales and fulfilment capabilities."
Klenk and its medicinal plant products are synonymous with quality and are made available across Germany and Europe through decades-long relationships with the leading European pharmaceutical wholesale distributors. Cannabis Klenk branded products are currently held in over 20 distribution hubs located across Germany to facilitate fast and uncomplicated access, as well as same-day delivery service to pharmacies where available.
Aurora's wholly owned subsidiary, Aurora Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada's Access to Cannabis for Medical Purposes Regulations (ACMPR). The company operates a 55,200-square-foot, state-of-the-art production facility in Mountain View county, Alberta, known as Aurora Mountain, and a second 40,000-square-foot high-technology production facility known as Aurora Vie in Pointe-Claire, Que., on Montreal's West Island. In January, 2018, Aurora's 800,000-square-foot flagship cultivation facility, Aurora Sky, located at the Edmonton International Airport, was licensed. Once at full capacity, Aurora Sky is expected to produce over 100,000 kilograms per annum of cannabis.
© 2018 Canjex Publishing Ltd. All rights reserved
Canopy Growth's Quebec JV receives licence to grow pot
2018-05-28 06:23 ET - News Release
VERT IS GROWING AGAIN: HEALTH CANADA GRANTS LICENCE TO VERT MIRABEL
Canopy Growth Corp. and Les Serres Stephane Bertrand Inc.'s joint business Les Serres Vert Cannabis Inc. (Vert Mirabel) received a cultivation licence from Health Canada on Friday, May 25, 2018. This establishes the 10th licenced production facility under the Canopy in Canada, moving the company officially into double digits. The company also possesses a sales-only licence located in Toronto.
The 700,000-square-foot Vert Mirabel greenhouse is licensed for an initial 40,000 square feet of growing space, increasing Canopy Growth's production footprint in Quebec and confirming its commitment to growing high-quality, made-in-Quebec cannabis to serve Quebeckers and ensure a strong offering to combat the illicit market in Quebec.
"We've been focused on building an industry-leading growing platform across Canada and this licence is our latest successful step as we execute our vision for a reliable supply chain for Canadians," said Mark Zekulin, president, Canopy Growth. "Vert Mirabel is a shared achievement and we are excited to see the execution demonstrated by Mon. Bertrand, his family and their entire team. Canopy Growth shares their deep commitment to a responsible and productive cannabis industry in Quebec."
"Now the real fun begins. We're excited to start applying our 27 years in greenhouse production and our expertise in organic tomato production to the cannabis plant," said Stephane Bertrand, executive director, Les Serres Stephane Bertand Inc. "We're proud and excited to be working alongside Canopy Growth to establish this important production site in Quebec."
In total, Canopy Growth's licensed growing space has tripled in calendar 2018 to more than 2.4 million square feet and remains on path to exceed 5.6 million square feet of domestic growing space to support medical and recreational customers from coast-to-coast.
Here's to future growth (in la belle province).
Canopy Growth is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and softgel capsule forms.
Canopy Growth has established partnerships with leading sector names including cannabis icon Snoop Dogg, breeding legends DNA Genetics and Green House seeds, and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy Growth operates eight cannabis production sites with over 2.4 million square feet of production capacity, including over 500,000 square feet of GMP-certified production space. The company has operations in seven countries across four continents.
Es scheint aber, nun kommt Geld für die Kanadier:
Aurora Cannabis Retains KCSA Strategic Communications to Enhance U.S. investor and Media Outreach
Aurora Cannabis Inc. (“Aurora” or the “Company”) (ACB.TO) (ACBFF) ( Frankfurt : 21P; WKN: A1C4WM) today announced it has appointed retained KCSA Strategic Communications (“KCSA”), a leading New York -based communications firm, to support the Company’s strategic communications and investor relations efforts in the United States .
“With American investor interest in Aurora growing rapidly, and a number of significant corporate developments on the way, this is the right moment for us to amplify our outreach to multiple U.S. audiences,” said Cam Battley , Chief Corporate Officer. “Given Aurora’s status as a global leader in the cannabis sector, we are adding skilled resources, both internally and externally, to help us share the Company’s story of agility, innovation and execution with institutional and retail investors in the U.S. and around the world.”
KCSA will implement a comprehensive communications program aimed at further increasing awareness of Aurora across the U.S. institutional and retail investment communities. Since its inception nearly fifty years ago, KCSA has developed a strong reputation for its work representing public companies, including a growing roster of cannabis companies.
Phil Carlson , Managing Director of KCSA Strategic Communications, commented, “Aurora has a clear and well-executed strategy, aimed at building a fully integrated and well-diversified cannabis company that meets all the critical success factors to capitalize on the global cannabis opportunity, estimated at approximately US$140 billion at maturity1 for the medical market alone. With our extensive history of providing expert strategic communications counsel based on best practices and large networks, we believe we are the right partner for Aurora to introduce this compelling story to a broader audience of institutional and retail investors, as well as to media and other influencers.”
The Company issued a total of 182,853 common shares of the Company to the vendors of CanvasRx for the achievement of certain performance milestones, pursuant to a share purchase agreement announced on August 10, 2016.
Aurora’s wholly-owned subsidiary, Aurora Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada’s Access to Cannabis for Medical Purposes Regulations (“ACMPR”). The Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta , known as “Aurora Mountain”, and a second 40,000 square foot high-technology production facility known as “Aurora Vie” in Pointe-Claire, Quebec on Montreal’s West Island. In January 2018 , Aurora’s 800,000 square foot flagship cultivation facility, Aurora Sky, located at the Edmonton International Airport, was licensed. Once at full capacity, Aurora Sky is expected to produce over 100,000 kg per annum of cannabis. Aurora is completing a facility in Lachute, Quebec utilizing its wholly owned subsidiary Aurora Larssen Projects Inc.
The Company’s wholly-owned subsidiary CanniMed Therapeutics Inc. (“CanniMed”) is Canada’s most experienced licensed producer of medical cannabis, with over 20,000 kg per annum in funded capacity. CanniMed forms the heart of Aurora’s Medical Cannabis Centre of Excellence, aimed at product and market development.
Aurora also owns Berlin -based Pedanios GmbH, the leading wholesale importer, exporter, and distributor of medical cannabis in the European Union. The Company owns 51% of Aurora Nordic, which will be constructing a 1,000,000 square foot hybrid greenhouse in Odense, Denmark . The Company offers further differentiation through its acquisition of BC Northern Lights Ltd. and Urban Cultivator Inc., industry leaders, respectively, in the production and sale of proprietary systems for the safe, efficient and high-yield indoor cultivation of cannabis, and in state-of-the-art indoor gardening appliances for the cultivation of organic microgreens, vegetables and herbs in home and professional kitchens.
Aurora holds a 25% ownership interest in Alcanna Inc. (“CLIQ”), one of Western Canada’s largest retail chains of liquor stores, who are developing a cannabis retail network in Western Canada . In addition, the Company holds approximately 17.23% of the issued shares in leading extraction technology company Radient Technologies Inc, and holds 52.7% of Hempco Food and Fiber Inc. Aurora is also the cornerstone investor in two other licensed producers, with a 22.9% stake in Cann Group Limited, the first Australian company licensed to conduct research on and cultivate medical cannabis, and a 17.62% stake in Canadian producer The Green Organic Dutchman Ltd., with options to increase to majority ownership. Finally, the Company owns a 9.14% stake in CTT Pharmaceutical, an innovative product development company within the cannabis space.
....sicher ist das mit Vorsicht zu geniessen. Als Cronos zur Nasdaq avisierte schoss der Kurs hoch - kaum dort ging es rasant bachab, da habe ich einen gewaltigen Schuh voll rausgezogen. Es hiess die Leerverkäufer hätten sich dort ihr Mütchen gekühlt, mit Erfolg - grrrrrrr
Ist hier jemand dabei? Mich dünkt der Kurs interessant, allerdings stellt sich mir die Frage, ob das Unternehmen nicht etwas viel am Hals hat mit seinen Grossinvestitionen?
Z.B.bei CGC gefiel mir der Verlauf recht gut, ich sorge mich zwar, weil sie an die US-Börse wollen. Das ist teuer und falls dort dann doch mal wieder ein Verbot befohlen wird, wäre das recht gefährlich für die Investierten. Trauen kann ich nicht mehr recht, wenn man dort Einzug hält. Nicht wegen CGC. Aber die wechselden Meinungen und Bestimmungen und Diktate dort, für diese Branche, dünken mich unabsehbar.
Ich habe heute zwei Nachrichten. Eine finde ich gut, die andere finde ich für mich nicht so beruhigend.
Nun, dies ist die gute Nachricht:
SMITHS FALLS, ON, May 14, 2018 /CNW/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) is pleased to announce that it has entered into a non-binding agreement (the "Agreement") to purchase, subject to certain conditions, the remaining 33% stake of BC Tweed Joint Venture Inc. ("BC Tweed") not currently owned by the Company. The consolidation of the two largest licensed cannabis facilities in the world into full Canopy Growth ownership cements the Company's commitment to shareholder value through scale production.
Canopy Growth, upon closing of the transaction, will issue up to $374 million worth of shares in the Company, subject to the satisfaction of certain conditions, to the minority shareholders of BC Tweed (the "Operators"). Payments are milestone-based and will be released over four years based upon the achievement of certain production milestones. The Operators, multi-generational cultivators, will continue to manage the BC-based operations for a period of 5 years.
The BC Tweed greenhouses represent a meaningful share of the entire Canadian production landscape with up to 3 million square feet of greenhouse growing capacity. Since the formation of BC Tweed in October of 2017, already over 1.7 million square feet has been licensed for production to meet to oncoming recreational cannabis demand across the country.
"Our provincial distribution agreements, commitment to quality and value-add processing, and leading brand portfolio position Canopy Growth as the market share leader in Canada's future recreational cannabis market," said Bruce Linton, Chairman & CEO, Canopy Growth. "Consolidating BC Tweed fully under the Canopy ensures that the full value of our strategic position is realized by Canopy shareholders."
Under the terms of the Agreement, subject to approval of the Toronto Stock Exchange and certain other conditions, the Company will issue $374 million worth of common shares in the capital of the Company based on the volume weighted average price per common share for the 20 trading day period ended May 11, 2018 (the "VWAP"). The Company will also pay $1 million in cash as a non-refundable deposit against the purchase price. In addition, the Company will issue $20 million worth of common shares in the capital of the Company at the same VWAP in connection with an option to acquire certain future infrastructure from the Operators, subject to certain conditions. The transaction is anticipated to close in early July, following the negotiation of definitive agreements.
Und diese hier, naja, ist Vertrauenssache, finde ich.-
SMITHS FALLS, ON, May 14, 2018 /CNW/ - Canopy Growth Corporation ("Canopy Growth" or the "Company")(TSX: WEED) announced today it has applied to list its common shares on the New York Stock Exchange (the "NYSE").
The Company currently anticipates that, subject to the receipt of all required approvals, its common shares will begin trading on the NYSE before the end of May 2018. In advance of listing on the NYSE, Canopy Growth will file a Form 40-F Registration Statement with the United States Securities and Exchange Commission. The listing of the Company's common shares on the NYSE remains subject to the approval of the NYSE and the satisfaction of all applicable listing and regulatory requirements.
Canopy Growth's common shares will trade on the NYSE under the ticker symbol "CGC" and will continue to trade on the TSX under the ticker symbol "WEED". A trading date will be made public once all regulatory formalities are satisfied.
In announcing the application to list on a U.S. stock exchange, Canopy Growth's Chairman & CEO, Bruce Linton, commented: "Since becoming the first regulated cannabis producer to list their shares in North America in 2014 our team has focused on building credibility through consistent execution. Once finalized, listing our shares on the NYSE will represent a continuation of our upward trajectory as we build the global cannabis industry."
Latest News, super (Man sollte wohl mal wieder eine rauchen...)
VANCOUVER, May 11, 2018 /CNW/ - INVICTUS MD STRATEGIES CORP. ("Invictus" or the "Company") (TSXV: GENE; OTC: IVITF; FRA: 8IS1) is pleased to announce that cannabis from the company's AB Laboratories Inc. (AB Labs) is now available for purchase through Canopy Growth Corporation's (TSX: WEED) Tweed Main Street online store and to-date AB Labs has transferred 172 KG of product to Canopy.
The strain Super Critical is available now as part of Tweed's elite CraftGrow line, and AB Labs anticipates shipping their other strains in the near future.
"Canadian medical cannabis patients value product diversity and we're committed to offering them an industry leading curated lineup from Tweed and our CraftGrow partners," said Mark Zekulin, President, Canopy Growth. "We're excited to welcome AB Labs product as the newest CraftGrow addition to the Tweed Main Street online store".
"The Canadian cannabis industry is diverse, dynamic and thriving, with valuable partnerships being forged every day," said Invictus founder and CEO Dan Kriznic. "Our collaboration with Canopy has already been enormously fruitful and rewarding. We look forward to working closely with this model of entrepreneurial fitness and efficiency as Canada's commercial cannabis market develops in coming months and years. I'm pleased to report that Invictus remains on track for achieving its substantial cultivation and harvest goals across 2018, and delivers more and more strains and cannabis volume into Canada's thriving consumer marketplace as Canada approaches legalization of the adult market. To further accommodate this the Company has developed a multifaceted sales strategy aimed to target each channel for sales and distribution such as establishing supply agreements and product calls with provincial governments and licensed producers, developing retail storefronts across Western Canada, and continuing to focus on the medical cannabis sector."
Tweed's highly curated CraftGrow line works only with top producers cultivating Canada's finest cannabis, and AB Labs is honored to have been the second cultivator to successfully transfer cannabis products to be sold though the e-commerce platform.
The Super Critical strain from AB Labs available on the platform is a high-yielding 50/50 hybrid of sativa and indica, a mix of Big Bud, Skunk and White Widow. The combination of exceptional yield plus superb flower makes it a favorite among growers.
AB Labs continues to make continuous progress on its 40,000 square foot Phase 2 facility, which once completed AB Labs will total 56,000 square foot of production capability. To-date in Phase 2 the interior demolition has been completed, cleaned and sanitized and all upgrades to the electrical and HVAC systems have also been completed. Construction of the mezzanine level has begun and overall progress is according to plan.
Invictus owns and operates cannabis companies in Canada with the vision of producing a variety of high quality and low cost cannabis products and strains to the global market place as regulations permit. Gene Simmons, music legend and media mogul, conveys the vision of Invictus as the Chief Evangelist Officer.
Invictus operates two cannabis production sites under the Access to Cannabis for Medical Purposes Regulations ("ACMPR") in Canada and has over 95,000 square feet of cannabis production capacity at the licensed production sites. The Company's wholly owned subsidiary Acreage Pharms Ltd. ("Acreage Pharms"), located in West-Central Alberta on 150 acres, has approximately 40,000 square feet of cannabis ready production with its recently completed Phase 2 expansion. The Company intends on expanding to 120,000 square feet by the end of 2018 once Phase 3 is complete.
Invictus also owns 50% of AB Laboratories Inc. ("AB Labs"), a licensed producer under the ACMPR located in Hamilton, Ontario. AB Labs currently operates in a 16,000 square foot facility and recently acquired a facility adjacent to the existing property that will allow for a total of 56,000 square feet of cultivation space expected to be ready for production by June 2018. During the first quarter of 2018 AB Labs submitted a secondary license to Health Canada for a nearby property on 100 acres under the name AB Ventures Inc. ("AB Ventures").
Combined, the licensed producers owned by Invictus expect to have approximately 200,000 square feet of cannabis production capacity by the end of 2018 and 520,000 square feet of cannabis production capacity by the end of 2019.
In addition to the ACMPR licenses, the Company has an 82.5% investment in Future Harvest Development Ltd. a high quality Fertilizer and Nutrients manufacturer based in Kelowna, British Columbia that has been in operation for over 20 years under the brand Plant Life Products and Holland Secret.
For more information, please visit www.invictus-md.com.
On Behalf of the Board,
Chairman & CEO
Vice President, Marketing & Communications
Heute bin ich mal mit aktuellen und erfreulichen News dabei:
SMITHS FALLS, ON and MELBOURNE, Australia, April 25, 2018 /CNW/ - Canopy Growth Corporation (TSX: WEED) ("Canopy Growth" or the "Company") is pleased to join the Victoria State Government in announcing the launch of the newest member of the Canopy Growth family, Spectrum Cannabis Australia ("Spectrum" or "Spectrum Australia").
Minister for Agriculture, the Hon. Jaala Pulford, alongside Ben Quirin, Managing Director of Spectrum Australia, announced the Company will invest up to $16 million AUD (~$16 million CAD) in the State of Victoria over the next four years to establish Spectrum's Asia-Pacific (APAC) headquarters and research and development facility.
"The State Government of Victoria has been an outstanding partner and welcomed our investment in the region with a shared passion for innovation in the medical cannabis industry," said Ben Quirin, Managing Director, Spectrum Australia. "Victoria is now home for Spectrum as we introduce our world renowned medical cannabis products to the State, across Australia, and throughout the entire APAC region as jurisdictions establish legal, regulated medical cannabis regimes."
The Victoria facility will enable domestic cultivation and production of high quality medical cannabis for patients while serving as a distribution hub for other jurisdictions in APAC. It will also operate as the APAC Research and Development Center for the Company, supporting the ongoing research collaboration between Spectrum Australia and Agriculture Victoria on innovations in medical cannabis cultivation and production.
"Collaborating with international experts on cultivation and manufacturing will build Victoria's capacity to develop our medicinal cannabis industry to be able to supply reliable and high quality medicinal cannabis products," said Minister for Agriculture, the Hon. Jaala Pulford.
The launch of Spectrum Australia builds on Canopy Growth's leadership position in the global medical cannabis space. Spectrum Australia's priority is to improve the lives of patients. This goal will be accomplished by focusing on three core areas:
This week Canopy Growth renewed its commitment to Australian partner, AusCann (ASX:AC8). Together with the State Government of Victoria and our strong local partner Spectrum Australia is committed to building an industry for the benefit of patients and healthcare professionals throughout APAC.
Spectrum Cannabis - Medical Cannabis. Simplified.
Learn more by visiting spectrumcannabis.com.au
About Spectrum Cannabis
Spectrum is an international cannabis business dedicated to improving the lives of patients and increasing cannabinoid knowledge within physician communities around the world. Its colour-coded strain classification system is available in Canada with operations underway in the European Union and South America, and Australia. Spectrum products are available in a range of potencies and formats designed to simplify the dialogue around strength and dosage by categorizing medical cannabis according to THC and CBD levels. Spektrum Germany Gmbh processes cannabis for sale in Germany in a GMP-certified facility and then distributes products to hundreds of German pharmacies. Spectrum Denmark is a partnership between Canopy Growth and Danish Cannabis. Through the partnership, Spectrum Denmark is developing a large-scale greenhouse facility in the city of Odense. Learn more at www.spectrumcannabis.com.au
About Canopy Growth Corporation
Canopy Growth is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time.
Canopy Growth has established partnerships with leading sector names including cannabis icon Snoop Dogg, breeding legends DNA Genetics and Green House seeds, and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy Growth operates eight cannabis production sites with over 2.4 million square feet of production capacity, including over 500,000 square feet of GMP-certified production space. The Company has operations in seven countries across four continents. The Company is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public's understanding of cannabis, and through its partly owned subsidiary, Canopy Health Innovations, has devoted millions of dollars toward cutting edge, commercializable research and IP development. Through partly owned subsidiary Canopy Rivers Corporation, the Company is providing resources and investment to new market entrants and building a portfolio of stable investments in the sector. From our historic public listing to our continued international expansion, pride in advancing shareholder value through leadership is engrained in all we do at Canopy Growth. For more information visit www.canopygrowth.com.
Ich sehe noch eine Info vom Montag und finde die wissenswert:
Canopy Growth's Canopy Health files provisional patents
2018-04-23 08:23 ET - News Release
Mr. Bruce Linton reports
CANOPY HEALTH INNOVATIONS FILES A SUITE OF ADDITIONAL CANNABIS-RELATED PATENTS
Canopy Health Innovations, the partly owned biopharmaceutical research and development affiliate of Canopy Growth Corp., has, alone or with its subsidiary Canopy Animal Health or through its joint venture Beckley Canopy Therapeutics, filed eight provisional U.S. patents pertaining to the delivery and application of cannabis and cannabinoid-based therapeutics in certain indications.
Specifically, the eight patent applications relate to the following:
In addition to updated applications relating to earlier Insomnia patent applications, this brings the total number of U.S. provisional patent filings (including Canopy Animal Health and Beckley Canopy Therapeutics) to 39.
These filings are part of a concerted plan to bring to patients and health care providers innovative medicines and health products targeting disease areas with substantial medical needs. As part of this plan, Canopy Health and its affiliates are collaborating with respected world-class academic researchers and clinicians, and working with leading research organizations and regulators in jurisdictions of interest to develop and register these breakthrough products.
"As global medical markets emerge the trend among regulators favours highly regulated and highly repeatable medical cannabis options," said Bruce Linton, chairman and chief executive officer, Canopy Growth. "Through Canopy Health's work we are bulding a body of knowledge around cannabinoid medicine that will lead to its inclusion in mainstream health care for the benefit of patients."
Canopy Health and its affiliates continue their practice of filing provisional patents in the United States, which is common in the field of intellectual property generation and protection. Patents are first filed in the United States to create a priority date and allow for future filings in other selected jurisdictions, including Canada.
Although cannabis is not presently federally legal in the United States for commercial purposes, it is still the most common "first to file" jurisdiction for intellectual property generation and protection activity pertaining to cannabis and cannabinoids.
Here's to future growth.
Ja Petra, das weiss man dort eben nie so genau...
16.04.2018 | 14:13
Smiths Falls, Ontario und Prag, Tschechische Republik (ots/PRNewswire) -
Canopy Growth Corporation (TSX: WEED) ("Canopy Growth" oder das "Unternehmen") freut sich anzukündigen, dass das Unternehmen endgültige Verträge zur Übernahme von Annabis Medical s.r.o ("Annabis Medical") unterzeichnet hat und damit den Fokus des Unternehmens in einen weiteren aufstrebenden Markt für medizinisches Cannabis erweitern wird. Dieses Geschäft soll am Montag, dem 16. April 2018 zum Abschluss gebracht werden.
Annabis Medical ist in der Tschechischen Republik Branchenführer für medizinisches Cannabis und importiert und vertreibt derzeit Cannabis-Produkte für den Verkauf über den Apotheken-Vertriebskanal im Rahmen tschechischer Lizenzen in der Tschechischen Republik. Sein Gründer und CEO, Dr. Robin Kazík, wird auch weiterhin das tschechische Tochterunternehmen als Teil der größeren Canopy Growth-Familie leiten und voranbringen.
"Diese Übernahme ist ein weiteres Beispiel für unser Engagement, die Präsenz von Canopy in Europa zu erweitern und unsere Führungsposition auszubauen", sagt Mark Zekulin, President von Canopy Growth. "Wir freuen uns darauf, tschechische Kunden mit unseren hochwertigen medizinischen Cannabis-Produkten aus GMP-Produktion zu beliefern und weitere Ressourcen zur Unterstützung der Weiterbildung tschechischer Apotheker, Patienten und medizinischer Fachkräfte bieten zu können."
Durch die Kombination des weitreichenden globalen Erfahrungsschatzes und Netzwerks mit der starken nationalen Position von Annabis Medical ist Canopy stolz, seine renommierte Marke Spectrum Cannabis auf einen weiteren europäischen Markt zu bringen.
"Mit einer soliden Präsenz und einem etablierten Vertriebsnetz auf dem tschechischen Markt für medizinisches Cannabis, sowie aufgrund der langjährigen Erfahrung beim Import von Cannabis aus Kanada freuen wir uns, zur Canopy Growth-Familie zu stoßen. Dieser Schachzug wird es uns ermöglichen, unser Produktangebot noch schneller zu diversifizieren, und unseren Zugang zu Rohmaterialien stärken, wenn wir im Markt wachsen", sagte Dr. Robin Kazík, Gründer und CEO von Annabis Medical.
Die Übernahme von Annabis Medical baut auf der Führungsposition von Canopy Growth im europäischen Segment für medizinisches Cannabis auf und folgt der kürzlich zustande gekommenen Partnerschaft und dem Liefervertrag mit dem führenden spanischen Pharmaunternehmen Alcaliber S.A. Darüber hinaus beliefert Canopy Growth derzeit schon den deutschen Markt über sein Tochterunternehmen Spektrum Cannabis GmbH und ist eine Partnerschaft mit Spectrum Cannabis Denmark ApS eingegangen, das über eine Lizenz für den Anbau von Cannabis in einer 40.000 Quadratmeter großen Treibhaus-Produktionseinrichtung in Odense, Dänemark, verfügt. Diese Aktiva, in Kombination mit den unvergleichlichen Produktions- und Vertriebsplattformen von Canopy Growth in Kanada, ergeben die am stärksten diversifizierte Cannabis-Plattform der Welt.
Gemäß den Vertragsbestimmungen wird das Unternehmen bei Abschluss 50.735 Stammaktien aus dem Eigenkapital mit einem Wert von CAD 1.491.882,70 an Dr. Kazík ausgeben und wird, vorbehaltlich der Erreichung bestimmter Meilensteine, bis zu 34.758 weitere Stammaktien mit einem Wert von CAD 1.022.080,00 (Basis 5-Tages-VWAP von CAD 29,40519 am 5. April 2018) ausgeben. Der Gesamtwert der im Rahmen des Vertrags zu zahlenden Vergütung beträgt ca. CAD 2.513.962,70. Sämtliche Beträge sind, soweit nicht anderweitig aufgeführt, in Kanadischen Dollar (CAD) angegeben.
Über Annabis Medical s.r.o
Annabis Medical s.r.o ist ein in der Tschechischen Republik ansässiger Lieferant von medizinischem Cannabis und hält seit 2014 entweder unmittelbar oder über Tochtergesellschaften Lizenzen für medizinisches Cannabis. Der Vertrieb von medizinischem Cannabis begann 2015, wobei das Unternehmen schon vorher mit Office of Medicinal Cannabis aus den Niederlanden zusammengearbeitet und zudem medizinisches Cannabis aus Kanada importiert hatte. Das Schwesterunternehmen Annabis, s.r.o. stellt Biokosmetik auf Hanfbasis her und ist nicht in die Transaktion involviert.
Jordan Sinclair, Director of Communications, Jordan@tweed.com, +1-613-769-4196; Investor Relations: Tyler Burns, Tyler.Burns@canopygrowth.com , +1-855-558-9333 ex 122; Director: Bruce Linton, email@example.com
OTS: Canopy Growth Corporation newsroom: http://www.presseportal.de/nr/121334 newsroom via RSS: http://www.presseportal.de/rss/pm_121334.rss2
© 2018 news aktuell
DELTA, BC, April 14, 2018 /CNW/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) is pleased to announce that yesterday it received additional licensing at both greenhouse facilities operating under its majority-owned BC Tweed Joint Venture banner, including the licensing of the largest cannabis facility in the world.
In particular, the already operating 1.3 million sq. ft. greenhouse facility in Aldergrove, BC, where 400,000 sq. ft. of canopy under glass was licensed in February, is now licensed for 840,000 sq. ft. of growing space.
The second BC Tweed site, totalling 1.7 million sq. ft. of greenhouse production space, also received a cultivation licence for its first 900,000 sq. ft. of growing space.
In total, Canopy Growth's licensed growing space has tripled in calendar 2018, to more than 2.4 million sq. ft. and remains on path to exceed 5.6 million sq. ft. of domestic growing space.
In consultation with IIROC and as a best practice, the Company decided to halt trading of its common shares on the TSX as soon as the licensing news was made public as the increased production capacity represents a material change in operations.
"This is all about focus and execution for our expanding team at Canopy Growth," said Mark Zekulin, President, Canopy Growth. "We have spent four years establishing the largest licensed cannabis production platform in the world. This afternoon with two key licensing milestones, we doubled it."
Want to learn more about our team at BC Tweed: visit us here.https://www.youtube.com/watch?v=c9qhIX7Kk_c
Here's to Future (BC) Growth (and BC Bud).
About BC Tweed Joint Venture
BC Tweed Joint Venture is a collaboration between Canopy Growth and an established, large-scale greenhouse grower to develop up to 3 million sq. ft. of high-end, automated greenhouse production space across two sites in beautiful British Columbia. Production is already underway to serve the growing demand for Canopy's family of genetics.
Trump Overrules Sessions: Promises To Protect States' Pot Legalization Rights
Three months after AG Sessions rescinded policies allowing states to legalize pot, President Trump has defused standoff with a top Republican (Colarado's Cory Gardner) and promised that he will support congressional efforts to protect states that have legalized marijuana.
.....kann man nur hoffen dass aus dem Hü nicht wieder ein Hott wird.....
Hast du einen Link zur Info oder den Text. Es wäre nett, wenn wir das sehen könnten. Danke.
SNB hat Canopy Aktien geposchtet - finde ich super!!!!
von heute, spannend:
Aurora Cannabis acquires Agropro, Borela hemp outfits
2018-09-12 08:22 ET - News Release
AURORA CANNABIS ACQUIRES EUROPE'S LARGEST ORGANIC HEMP COMPANY
Aurora Cannabis Inc. has acquired Europe's largest producer, processor and supplier of certified organic hemp and hemp products, Agropro UAB, as well as hemp processor and distributor Borela UAB.
Agropro, a hemp seed contracting and processing company, and its sister company Borela UAB, a processor and distributor of organic hulled hemp seeds, hemp seed protein, hemp flour and hemp seed oil, currently has 1,600 hectares (4,000 acres) under contract, potentially yielding more than one million kilograms of organic hemp with additional contracts available to expand to more than 3,000 hectares across Lithuania, Latvia, Estonia and Poland.
Previously, the companies were focused exclusively on the production and sale of hemp-seed-based products to markets across Europe, North America and Asia. Each year, very substantial quantities of CBD (cannabidiol) containing hemp biomass were left on the field unutilized.
Postacquisition, Aurora intends to extract, refine and productize the organic hemp biomass into a wide range of organic CBD-based wellness products to generate new and significant revenue streams in this burgeoning market. With increasing recognition of the medical and general health benefits of CBD-based products, Aurora continues executing on a CBD-focused strategy that covers the entire value chain, from supply, through genetics research and clinical trials, to product development and distribution to various domestic and international markets across five continents.
In addition to the CBD-related market potential, hemp is an increasingly sought-after food supplement and meat substitute for the large and rapidly growing health food, vegetarian and vegan markets, due to its high protein content. Through its majority-owned subsidiary Hempco, Aurora is already executing on a number of hemp food market opportunities, and intends to integrate Agropro's organic supply and distribution with Hempco's to enhance market access and accelerate growth of high-margin, premium hemp-based product offerings.
On Feb. 1, 2018, Borela's hemp grain processing facility became the only European hemp company to receive a BRC quality certificate, enabling Borela to supply supermarkets with its product. Borela's operations have also received USDA Organic, Eco-Cert, as well as other certifications, enabling the company to market premium products across large markets.
The organic certification achieved by both Agropro and Borela will enable the launch of new premium products, positively impacting the company's margin profile for hemp-based products.
"Agropro's position as Europe's leading producer of premium organic hemp along with the significant and previously unutilized CBD production from the large quantities of currently discarded biomass, makes this an accretive acquisition and one that positions Aurora well to become a global leader in organic CBD-based wellness products," said Terry Booth, chief executive officer.
Neil Belot, chief global business development officer, added: "With our industry-leading team of crop and plant scientists, extraction and product formulation expertise, and wide-reaching global distribution networks and partnerships, we anticipate increasing production, extraction, refinement and supply of CBD, as well as other hemp-based food products. With a broad European footprint, extensive contracted land agreements and solid existing revenue streams, Agropro and Borela provide further expansion of our international footprint, while playing an important role in the execution of our CBD wellness and hemp-based food products strategy."
Skirmantas Nikstele, co-founder and chief executive officer of Agropro, added: "As the largest producer, processor and supplier of organic hemp products in Europe, we have developed a strong reputation for quality and consistency with our customers across the globe. Through Aurora, we gain access to a wider distribution network, as well as an access to industry-leading science to help ramp up production, while enhancing margins through the introduction of new products, proven production techniques and robust genetics."
Hemp -- superfood with high market growth
The hemp plant is made up of three components. Seeds, which are used in food and personal care products, leaves and flowers, which produce cannabidiol (CBD), used in medical products, supplements and beauty products, and stalk, which produces fibre and hurd, used in paper products, building materials, clothing and other textiles.
Hemp seed oil offers the richest and most balanced source found in nature of essential fatty acids (EFAs), such as omega 3 and omega 6 oils. EFAs play a very important role in critically important processes, such as detoxification and the formation of brain cells, hormones and neurotransmitters. Hemp seed is not only rich in essential fatty acids, it also represents an important source for amino acids, which are the building blocks of protein. Essential amino acids are not produced by our bodies, and therefore must come from food. Hemp seeds contain all nine essential amino acids, as well as other nutritionally important vitamins and minerals, such as iron, zinc, carotene, vitamin B1, vitamin B2, vitamin B6, vitamin D, vitamin E, calcium, magnesium, potassium and enzymes.
These characteristics have resulted in strong continued market growth of hemp-based products. Grand View Research (industrial hemp market size, share and trends analysis, 2018) anticipates the industrial hemp market to grow at a compound annual growth rate of 14.0 per cent to $10.6-billion (U.S.) by 2025. The hemp seed market, as a subcategory, is anticipated to show even stronger growth.
With Agropro and Borela, Aurora has acquired a very substantial supply of organic hemp seed products, as well as the capacity to process the raw material into products, and the international distribution channels to sell these. Market reach will be further strengthened through integration with Hempco, while Aurora's science teams will be spearheading research into cultivation yield enhancements, as well as further medical and wellness applications.
Terms of the transaction
Aurora purchased 100 per cent of the issued and outstanding shares of Agropro UAB and Borela UAB for total cash consideration of 5,364,000 euros (approximately $8.1-million (Canadian)) and common shares of Aurora equivalent to 960,000 euros (approximately $1.4-million (Canadian)), based on the five-day volume-weighted average price as of Sept. 10, 2018. In addition, Aurora will also refinance existing debt totalling 2,076,000 euros (approximately $3.1-million (Canadian)) and provide a finder's fee totalling 1,517,400 euros (approximately $2.3-million (Canadian)).
Headquartered in Edmonton, Alta., Canada, with financed capacity in excess of 570,000 kilograms per year and sales and operations in 14 countries across five continents, Aurora is one of the world's largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, and wholesale and retail distribution.
Der Kommentar von Ben wurde ignoriert. Um die Kommentare von Ben wieder zu sehen, klicken Sie folgenden Link:
Aurora Cannabis to Acquire South American Market Leader ICC Labs.
Aurora erhält eine HealthCanada-Produktionslizenz für seine Aurora Eau Anlage in Lachute/Que.
Aurora Cannabis Inc. hat für seine Aurora Eau-Anlage in Lachute, Que, eine Health Canada-Produktionslizenz erhalten. Das Unternehmen verfügt nun über sieben Produktionsstätten mit einer Produktionskapazität von über 160.000 Kilogramm pro Jahr. Aurora hat zusätzliche Anlagen in Entwicklung, so dass die gesamte finanzierte Kapazität auf mehr als 500.000 Kilogramm pro Jahr steigt. Darüber hinaus hat Aurora über seine hundertprozentige Tochtergesellschaft Medreleaf Corp. die Lizenz zur Herstellung von Öl für sein Werk in Bradford erhalten, das bei voller Kapazität eine Anbaufläche von 28.000 Kilogramm pro Jahr hat. Medreleaf Bradford verfügt über eine großvolumige Kohlendioxid-Extraktionsanlage, die die Ölproduktion erheblich steigern wird und in Erwartung des Erhalts der Verkaufslizenz erhebliche Mengen an Derivaten vorrätig hält. Aurora Eau, eine 48.000 Quadratfuß große Einrichtung mit einer Produktionskapazität von 4.500 Kilogramm pro Jahr, wurde speziell für die GMP-Standards (Good Manufacturing Practices) der Europäischen Union entwickelt und repräsentiert die nächste Entwicklung der Indoor-Grow-Anlagen von Aurora. Aurora Eau wurde gebaut, um Flexibilität in allen wichtigen Produktionsparametern zu ermöglichen, um die aktuellen exotischen Sorten des Unternehmens sowie neue Stämme, die noch nicht eingeführt wurden, und neue Genetik, die für den medizinischen Gebrauch und den Gebrauch für Erwachsene bestimmt sind, optimal anzupassen. Aurora Eau liegt in Lachute, Que., Und liegt auf einem 46 Hektar großen landwirtschaftlichen Nutzland, das Aurora für 136.000 Dollar für künftige Expansionszwecke erwerben kann. Dies würde die gewichtete Präsenz des Unternehmens in Quebec erweitern und zusätzliche Kapazitäten für die künftige Produktentwicklung und den Vertrieb bieten. Das Unternehmen wird sich wie auch seine anderen Einrichtungen im Rahmen der Verpflichtung des Unternehmens zum Aurora-Standard und zur weiteren Diversifizierung der Lieferkette auf dem Weg zu einer EU-GMP-Zertifizierung fortentwickeln. Bis heute hat Aurora zwei EU-GMP-Anbauanlagen in Kanada sowie eine EU-GMP-zertifizierte Einrichtung in Deutschland, die von ihrer hundertprozentigen Tochtergesellschaft Aurora Europe GmbH betrieben wird, für den Import, die Freisetzung und den Vertrieb von Cannabis. Der Anbau begann in Eau Der Anbau hat bei Aurora Eau begonnen, nachdem eine Mischung aus Klonen und ausgereiften Pflanzen mit einem maßgeschneiderten, umweltfreundlichen Transporter erhalten wurde, der von Auroras hundertprozentiger Tochter B.C. Nordlichter. Der neue Transporter ermöglicht es Aurora, große Mengen von Klonen und Müttern kostengünstig zu transportieren, was eine schnelle Ansiedlung neuer Einrichtungen ermöglicht. Nach dem erfolgreichen Transfer ist Aurora Eau jetzt in voller Produktion. Managementkommentar "Wir sind stolz auf die Errungenschaften von Aurora Eau und mit sieben Produktionslizenzen sind wir außerordentlich gut positioniert, um sowohl auf dem kanadischen als auch auf dem internationalen Markt weiter auf dem Markt zu bestehen", sagte Terry Booth, Chief Executive Officer von Aurora. "Mit der großtechnischen Produktion bei Aurora Sky haben wir die Möglichkeit, die Produktion von Aurora Eau in Nischenmärkten zu investieren, wodurch wir unsere Markenbekanntheit steigern und unser Margenprofil verbessern. Unsere neue Ölproduktionslizenz in Bradford erhöht unsere Produktionskapazität weiter höhermargige Öle und treiben Wachstum. "
Ja, bin auch (wieder) drin. Habe gesehen, dass das Q4/2018 am 25.10.2018 gezeigt wird und das Q1/2019 am 29.10.2018, Highlights
Und dies ist noch vom Dienstag in dieser Woche, also vom 4.9.18:
Aurora Cannabis Closes $200 Million Debt Facility with BMO
Historic Financing with a Canadian Tier 1 Bank Provides Additional Capital to Drive Growth
EDMONTON, Sept. 4, 2018 - Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) today announced that it has closed its previously announced debt facility with the Bank of Montreal ("BMO"). The facility consists of a $150 million term loan and a $50 million revolving credit facility (together, the "Loans"), both of which mature in 2021. Included in the facility is an option to upsize the facility to $250 million total following the implementation of Bill C-45 on October 17, 2018, subject to agreement by BMO and satisfaction of certain legal and business conditions.
The debt facility is primarily secured by Aurora's production facilities, including Aurora Sky, Aurora Mountain, and Aurora Vie. Strategically located at Edmonton International Airport, Aurora Sky is the world's most technologically advanced cannabis facility, projected to produce in excess of 100,000 kg per year of high-quality, low-cost per gram, cannabis upon completion.
"We are incredibly proud to have successfully closed this historic debt facility supported by a premier Canadian bank, BMO, who understands our needs and potential. This is both a reflection of the rapidly maturing nature of the broader cannabis industry and strong validation of the economic potential of Aurora's best-in-class, technologically advanced production facilities," said Terry Booth, CEO of Aurora. "With BMO and the syndicate lenders, Aurora gains significant runway to expansion opportunities that will positively contribute to our long-term margin profile and provide accelerated entry into multiple international markets. This additional capital positions us well to continue building the pre-eminent global cannabis company with a focus on vertically integrated, geographically and horizontally diversified assets."
Glen Ibbott, CFO of Aurora, added, "The closing conditions of this debt facility included stringent due diligence of Aurora's current production facilities as well as a thorough review of Aurora's projected revenue growth across all of our divisions. With our extremely strong balance sheet, Aurora is well positioned to execute on our business strategy, including accelerated development and launch of new products, continued rapid expansion of our domestic and international operations, and entry into new global markets."
Pursuant to the agreed upon conditions of the Loans, Aurora may, at its discretion, repay the balance of the Loans without penalty, at any time. The pricing of the Loans is a set margin over the BMO CAD Prime Rate or a Bankers' Acceptance of appropriate term. Based on the current BMO CAD Prime Rate, the interest payable is expected to be in the mid to high 4% per annum range over the term of the Loans. Additional details on this new sector benchmark debt facility can be found in the Company's documents that have been filed on www.sedar.com.
Headquartered in Edmonton, Alberta, Canada with funded capacity in excess of 570,000 kg per year and sales and operations in 14 countries across five continents, Aurora is one of the world's largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.
Highly differentiated from its peers, Aurora has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale production of high quality product at ultra-low costs. Intended to be replicable and scalable globally, these production facilities are designed to produce cannabis of significant scale, with high quality, industry-leading yields, and ultra-low per gram production costs. Each of Aurora's facilities is built to meet European Union (EU) GMP standards, and its first production facility, the recently acquired MedReleaf Markham facility, and its wholly owned European medical cannabis distributor Aurora Europe GmbH, have achieved this level of certification.
In addition to the Company's rapid organic growth and strong execution on strategic M&A, which to date includes 10 companies acquired – MedReleaf, CanvasRx, Peloton Pharmaceutical, Pedanios, H2 Biopharma, Urban Cultivator, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics, and Anandia – Aurora is distinguished by its reputation as a partner of choice and employer of choice in the global cannabis sector, having invested in and established strategic partnerships with a range of leading innovators, including: The Green Organic Dutchman Holdings Ltd. (TSX: TGOD), Radient Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV: HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), Namaste Technologies Inc. (TSXV: N), Evio Beauty Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC: CTTH), Capcium Inc. (private), and Alcanna Inc. (TSX: CLIQ).
Aurora's Common Shares trade on the TSX under the symbol "ACB", and are a constituent of the S&P/TSX Composite Index.
For more information about Aurora, please visit our investor website, investor.auroramj.com, Twitter, Facebook or Instagram.
Terry Booth, CEO
Aurora Cannabis Inc.
Forward looking statements
Ich bin nun da auch dabei, Aurora dürfte steigen.
Grüsse von fern zurzeit
Der Kommentar von brancusi-serrat wurde ignoriert. Um die Kommentare von brancusi-serrat wieder zu sehen, klicken Sie folgenden Link:
der Aktionär heute:
Geträncke-Hersteller werden dabei sein.
Emil hat am 04.09.2018 18:00 geschrieben:
Canopy Growth ist heute bereits wieder 10% gestiegen.
Ich bevorzuge nach wie vor Kanada, also Toronto, WEED.
Canopy Growth ist heute bereits wieder 10% gestiegen.
Ich bevorzuge nach wie vor Kanada, also Toronto, WEED.
....da kann ich nur hoffen, dass Du früh rein bist und drin geblieben....hier mein mieses Beispiel: 5000 Canopy zu C$ 2.76 gekauft am 22.07.2016
verkauft zu C$ 4.07 am 10.08.2016 - und ich kam mir vor wie ein Krösus und war doch die dümmste Nuss, nie mehr rein aus weiss ich was für Gründen
könnte mir ohrfeigen...
Der Aktionär: http://www.deraktionaer.de/aktie/cannabis-aktien--canopy-growth--aurora-cannabis-und-co-brechen-ein---droht-aerger-aus-den-usa--397050.htm
Cannabis-Aktien: Canopy Growth, Aurora Cannabis und Co brechen ein – droht Ärger aus den USA?
Michel Doepke | Redakteur
14.09.2018 - 08:59 Uhr
AURORA CANNABIS5,40 € -2,70%CANOPY GROWTH38,90 € -1,44%TILRAY CL.294,70 € -6,45%
Die boomende kanadische Cannabis-Industrie scheint den USA ein Dorn im Auge zu sein. Wie das Magazin Politico berichtet, gibt es Überlegungen, gegen Pot-Investoren sowie -Arbeiter ein Einreiseverbot zu verhängen. Die Hintergründe für den Vorstoß liegen auf der Hand: Frisches Öl ins Handelsstreit-Feuer zwischen den USA und Kanada gießen.
Wie ein hochrangiger Beamter für Grenzkontrollen gegenüber Politicoverlauten ließ, könnten Marihuana-Raucher aus den USA verbannt werden. "Unsere Beamten werden nicht alle Einreisenden fragen, ob sie Marihuana konsumieren. Aber wenn Fragen in diese Richtung führen oder ein entsprechender Geruch aus dem Auto kommt, könnten wir eine Befragung durchführen", so Todd Owen.
Viel Rauch um wenig
Den USA geht es weniger um den Cannabis-Konsum an-sich. Eher geht es den Vereinigten Staaten darum, von der boomenden Industrie in Kanada überrollt zu werden. Schließlich wird dem Cannabis-Markt ein Multi-Milliarden-Potenzial nachgesagt. Zudem enstehen eine Vielzahl neuer Arbeitsplätze in der Branche.
Trotzdem sorgte der Bericht für stark fallende Notierungen bei den Cannabis-Aktien. Canopy Growth verlor im regulären Handel knapp 14 Prozent, Aurora Cannabis neun Prozent. Cronos, auf die sich die Shortseller von Citron Research eingeschossen haben, verlor ebenfalls gut zehn Prozent an Wert. Ein großer Pot-Stock konnte sich, zumindest im regulären Handel, mit einem satten Plus aus der Affäre ziehen: Tilray. Wie das Cannabis-Unternehmen gestern vorbörslich bekannt gab, werde man fortan Cannabisöl und -blüten nach Deutschland liefern. In der Spitze schoss das Papier auf 127,27 Dollar. Ein neues Rekordhoch. Nachbörslich verlor die Tilray-Aktie dann doch über fünf Prozent.
Nichts für schwache Nerven
Der Cannabis-Sektor ist in den vergangenen Wochen heiß gelaufen. Kein Wunder, dass die Cannabis-Aktien in der Folge mit satten Kursverlusten reagierten. Davon sollten sich investierte Anleger jedoch nicht verunsichern lassen. Fakt ist: Die Legalisierungswelle rollt, in Kanada wird es am 17. Oktober 2018 soweit sein. DER AKTIONÄR hat in der neuen Ausgabe die Branche genauer unter die Lupe genommen und erklärt in der Story, welche Aktien noch kaufenswert sind. Das ePaper steht Ihnen hier zum Download zur Verfügung.
Selector hat am 13.09.2018 17:55 geschrieben:
Hast du einen Link zur Info oder den Text. Es wäre nett, wenn wir das sehen könnten. Danke.
Nationalbank: Jetzt auch Big in Haschisch-Aktien
12.9.2018 Lukas Hässig
Währungshüter kaufen alles auf, was ihnen in die Hände kommt – Neuerdings Gross-Aktionärin von „First Cannabis Company“....
.....ich nehme an es stimmt - sonst wäre sicher ein shitstorm losgebrochen.
CocaCola möchte Cannabis-Drinks herstellen und befindet sich offenbar in Gesprächen mit Aurora. Die Gespräche sollen weit fortgeschritten sein.
Offenbar Gespräche mit Aurora
Coca-Cola will Cannabis-Drinks herstellen
Die Gespräche laut Insidern seien "ziemlich weit fortgeschritten".
An alkoholische Getränke hat sich Softdrink-Riese Coca-Cola bereits herangewagt. Nun will der Konzern einem Medienbericht zufolge auch cannabishaltige Drinks entwickeln. Sie sollen gegen Schmerzen und Krämpfe wirken.
Coca-Cola hat offenbar Interesse am Einstieg in die Herstellung von cannabishaltigen Getränken. Dem kanadische Business-Sender "BNN Bloomberg" zufolge verhandelt der Konzern diesbezüglich mit Aurora, einem der größten kanadischen Cannabis-Hersteller. Die Nachricht versetzte Aurora-Anleger sogleich in einen Kaufrausch: Die Aktien stiegen an der Börse in Toronto um bis zu 22 Prozent auf 10,42 Dollar.
Coca-Cola und Aurora teilten in getrennten Erklärungen mit, man schaue sich die Entwicklung am wachsenden Markt von mit Marihuana versetzten Getränken genau an. Ansonsten kommentiere man aber keine Marktspekulationen. Auch "BNN Bloomberg" zufolge gibt es keine Garantie dafür, dass die Gespräche erfolgreich verlaufen. Die beiden Unternehmen werden demnach wahrscheinlich aber Drinks entwickeln, die bei Schmerzen, Entzündungen und Krämpfen wirken, meldete der Sender unter Berufung auf Insider. Die Gespräche seien "ziemlich weit fortgeschritten".
Bei den mit Marihuana versetzten Getränken geht es um den Wirkstoff Cannabidiol (CBD), der als nicht suchtfördernd oder berauschend gilt. Dem Deutschen Hanfverband zufolge gilt CBD zudem als relativ arm an Nebenwirkungen. Als Ausnahmemedikation bei schweren Erkrankungen kann Cannabis in Deutschland seit März letzten Jahres gegen Schmerzen verordnet werden. Aus der Hanfpflanze wird aber auch das "high" machende Tetrahydrocannabinol (THC) gewonnen.
Kanada und einige US-Bundesstaaten haben Marihuana auch für nicht medizinische Zwecke als Genussmittel legalisiert. Nach dem US-Bundesrecht bleibt der Handel damit aber verboten, weshalb viele US-Konzerne vorsichtig sind.
Bisher haben sich nur Alkohol-Hersteller auf den Markt vorgewagt. So hat der Hersteller von Corona-Bier Constellation Brands mehr als vier Milliarden Dollar in Canopy Growth - ebenfalls aus Kanada - investiert, um auf Cannabis basierende Getränke zu produzieren. Analysten rechnen nun damit, dass auch der Cola-Rivale Pepsi an dem Markt interessiert sein dürfte.
Aurora Cannabis6,59 19,8%
© 1998-2019 / cash
| Impressum |